Harvard Bioscience
HBIO
99 hedge funds and large institutions have $192M invested in Harvard Bioscience in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 34 reducing their positions, and 11 closing their positions.
522% more call options, than puts
Call options by funds: $112K | Put options by funds: $18K
12% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 34
0% more funds holding
Funds holding: 99 → 99 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
0.24% less ownership
Funds ownership: 6.98% → 6.74% (-0.24%)
17% less capital invested
Capital invested by funds: $232M → $192M (-$40.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$4.3M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.3M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$581K |
| 4 |
GC
Globeflex Capital
San Diego,
California
|
+$553K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$539K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$2.79M |
| 2 |
RA
Royce & Associates
New York
|
-$1.56M |
| 3 |
Renaissance Technologies
New York
|
-$1.25M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$1.08M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$988K |
HBIO Hedge Fund Activity: Q3 2021 in Review
99 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2021, worth a combined $192M — down 17% from $232M a quarter earlier.
Fund positioning in HBIO was balanced in Q3 2021: 11 funds opened new positions, 11 closed out, 38 added to existing stakes and 34 trimmed.
The largest buyer was Portolan Capital Management, adding an estimated $4.3M. The largest seller was Heartland Advisors, cutting an estimated $2.79M.
- 99 institutional investors held Harvard Bioscience (HBIO) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $192M of Harvard Bioscience stock for Q3 2021, down 17% quarter-over-quarter.
- 11 funds opened new Harvard Bioscience positions in Q3 2021 and 11 closed out, a net change of 0 holders.
- The largest Harvard Bioscience buyer in Q3 2021 was Portolan Capital Management, an estimated $4.3M added.
- The largest Harvard Bioscience seller in Q3 2021 was Heartland Advisors, an estimated $2.79M sold.
Based on aggregated 13F filings for Q3 2021.